<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01984086</url>
  </required_header>
  <id_info>
    <org_study_id>200921</org_study_id>
    <nct_id>NCT01984086</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetic Profile of Salbutamol Delivered by Unit Dose Dry Powder Inhaler (UD-DPI) Compared to the Diskus and Metered Dose Inhaler (MDI) in Healthy Volunteers.</brief_title>
  <official_title>An Open-label, Randomised, Cross-over, Two Cohort, Single Dose Study in Healthy Volunteers to Evaluate the Unit Dose Dry Powder Inhaler (UD-DPI) for the Delivery of Salbutamol and to Compare the Pharmacokinetic Profile With the MDI and Diskus Presentations.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, two part, six period- cross over, randomised, single dose, single&#xD;
      centre study in healthy subjects. This is the first clinical study for the UD-DPI. This study&#xD;
      is divided into two parts. Part A will ascertain whether the pharmacokinetic (PK) of&#xD;
      salbutamol delivered via the UD-DPI is comparable to the salbutamol delivered via the Diskus&#xD;
      or MDI. For this reason four treatment doses consisting of three dose strength and two&#xD;
      percentage blends will be assessed in Part A delivered via UD-DPI. Part A will also provide&#xD;
      preliminary PK variability estimates to allow for better sample size/precision calculations&#xD;
      for Part B. Part B will explore whether the UD-DPI has a pharmacokinetic exposure profile&#xD;
      that is comparable to either Diskus or MDI in the presence of the charcoal block.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 21, 2013</start_date>
  <completion_date type="Actual">May 26, 2014</completion_date>
  <primary_completion_date type="Actual">May 26, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Pharmacokinetics parameters of single doses of salbutamol in healthy subjects delivered via the UD-DPI device, using a range of doses and blends, and to compare to MDI and Diskus</measure>
    <time_frame>Day 1 of each treatment period (Pre dose and 0 hr, 2 minute [min], 5 min, 10 min, 20 min, 30 min, 45 min, 1hr, 1.5 hr, 2hr, 4 hr, 6 hr, 8 hr, 10 hr and 12 hr post dose)</time_frame>
    <description>PK parameters include: area under the concentration-time curve from time zero (pre-dose) to 12 hours (hr) (AUC [0-12hr]) and/ or area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC [0-infinity]) and/ or area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC [0-t]) and maximum observed concentration (Cmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Pharmacokinetics parameters of salbutamol in healthy subjects delivered via UD-DPI versus Diskus and/or MDI with charcoal blockade.</measure>
    <time_frame>Day 1 of each treatment period (Pre dose and 0 hr, 2 minute [min], 5 min, 10 min, 20 min, 30 min, 45 min, 1hr, 1.5 hr, 2hr, 4 hr, 6 hr, 8 hr, 10 hr and 12 hr post dose)</time_frame>
    <description>PK parameters include: AUC(0- infinity) or AUC(0-t) and Cmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Pharmacokinetic parameters following single doses of salbutamol and different blends of salbutamol in healthy subjects delivered via UD-DPI</measure>
    <time_frame>Day 1 of each treatment period (Pre dose and 0 hr, 2 minute [min], 5 min, 10 min, 20 min, 30 min, 45 min, 1hr, 1.5 hr, 2hr, 4 hr, 6 hr, 8 hr, 10 hr and 12 hr post dose)</time_frame>
    <description>PK parameters include: area under the concentration-time curve from time zero (pre-dose) to 30 min (AUC [0-30 min]) and time to maximum observed concentration (tmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Pharmacokinetic parameters following single doses of salbutamol in healthy subjects delivered via UD-DPI , MDI and Diskus with/ and without charcoal</measure>
    <time_frame>Day 1 of each treatment period (Pre dose and 0 hr, 2 minute [min], 5 min, 10 min, 20 min, 30 min, 45 min, 1hr, 1.5 hr, 2hr, 4 hr, 6 hr, 8 hr, 10 hr and 12 hr post dose)</time_frame>
    <description>PK parameters include: AUC [0 30 min] and tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Number of subjects with adverse events (AEs)</measure>
    <time_frame>Up to 14 days after the last dose of study treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Safety and tolerability of salbutamol, as assessed vital signs</measure>
    <time_frame>Day 1 of each treatment period</time_frame>
    <description>Vital sign measurements to be measurement include systolic and diastolic blood pressure and pulse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Safety and tolerability of salbutamol, as assessed by 12-lead electrocardiogram (ECG) parameters</measure>
    <time_frame>Day 1 of each treatment period</time_frame>
    <description>Single 12-lead ECGs will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT interval using Fredericia's formula (QTcF) intervals.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive following six treatments each in six period, with a 3-days minimum wash-out period, between each treatment period: 1) Single dose (SD) salbutamol (200mcg per blister from 1.6% blend) delivered via the UD-DPI by inhalation of 3 Blisters (BTR) giving a total dose of 600mcg; 2) SD salbutamol sulphate (200mcg per BTR from a 1.0% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 600mcg; 3) SD salbutamol (150mcg per BTR from a 1.6% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 450mcg; 4) SD salbutamol (250mcg per BTR from a 1.6% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 750mcg; 5) SD of salbutamol (200mcg per BTR) delivered via the Diskus by inhalation of 3 BTR giving a total dose of 600mcg; 6) SD salbutamol (100mcg per actuation) delivered via the MDI giving a total dose of 600mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prior to the start of Part B, a decision will be made regarding the UD-DPI products to be used in Part B. Subjects will receive following 6 treatments each in 6 period, with a 3-days minimum wash-out period, between each treatment period: 1) SD salbutamol (selected from Part A) delivered via the UD-DPI without activated charcoal (AC) by inhalation of 3 BTR (total dose dependant on UD-DPI formulation chosen); 2) SD salbutamol (selected from Part A) delivered via the UD-DPI with AC by inhalation of 3 BTR (total dose dependant on UD-DPI formulation chosen); 3) SD salbutamol by inhalation of 3 BTR (200mcg per BTR) delivered via the Diskus without AC (total dose 600mcg); 4) SD salbutamol by inhalation of 3 BTR (200mcg per BTR) delivered via the Diskus with AC (total dose 600mcg); 5) SD salbutamol 6 inhalations (100mcg) delivered via the MDI without AC (total dose 600mcg); 6) SD salbutamol 6 inhalations (100mcg) delivered via the MDI with AC (total dose 600mcg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend)</intervention_name>
    <description>Salbutamol Sulphate 150mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients</description>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend)</intervention_name>
    <description>Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients</description>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend)</intervention_name>
    <description>Salbutamol Sulphate 250mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients</description>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol Sulphate 200mcg UD-DPI Blister(1% blend)</intervention_name>
    <description>Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients</description>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol Diskus 200mcg Blister</intervention_name>
    <description>Salbutamol Diskus 200mcg will be supplied as blister strip contained within the Diskus device. Each blister contains a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients</description>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol MDI 100mcg</intervention_name>
    <description>Salbutamol MDI 100mcg will be supplied as formulation of salbutamol sulphate (micronized) in propellant contained within the pressurised MDI device</description>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol Sulphate UD-DPI Blister (selected from Part A)</intervention_name>
    <description>Formulation will be determined depending on the outcome of Part A.</description>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol Sulphate 250mcg UD-DPI Blister (selected from Part A)</intervention_name>
    <description>Formulation will be determined depending on the outcome of Part A.</description>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol Diskus 200mcg Blister without activated charcoal</intervention_name>
    <description>Formulation will be determined depending on the outcome of Part A.</description>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol Diskus 200mcg Blister with activated charcoal</intervention_name>
    <description>Formulation will be determined depending on the outcome of Part A.</description>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol MDI 100mcg without activated charcoal</intervention_name>
    <description>Formulation will be determined depending on the outcome of Part A.</description>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol MDI 100mcg with activated charcoal</intervention_name>
    <description>Formulation will be determined depending on the outcome of Part A.</description>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Male/females aged between 18 and 65 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Body weight &gt;=50 kg and body mass index within the range 19.0 - 34.0 kilogram per&#xD;
             square meter (inclusive).&#xD;
&#xD;
          -  A female subject is eligible to participate if she is of: Non-childbearing potential&#xD;
             defined as pre-menopausal females with a documented tubal ligation or hysterectomy for&#xD;
             this definition, &quot;documented&quot; refers to the outcome of the investigator's/designee's&#xD;
             review of the subject's medical history for study eligibility, as obtained via a&#xD;
             verbal interview with the subject or from the subject's medical records; or&#xD;
             postmenopausal defined as 12 months of spontaneous amenorrhea in questionable cases a&#xD;
             blood sample with simultaneous follicle stimulating hormone (FSH) &gt;40&#xD;
             milli-international units per milliliter (MlU/mL) and estradiol &lt; 40 picograms per&#xD;
             milliliter (pg/mL) (&lt;147 picomole per liter) is confirmatory. Females on hormone&#xD;
             replacement therapy (HRT) and whose menopausal status is in doubt will be required to&#xD;
             use one of the contraception methods in listed in protocol if they wish to continue&#xD;
             their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation&#xD;
             of post-menopausal status prior to study enrollment. For most forms of HRT, at least&#xD;
             2-4 weeks will elapse between the cessation of therapy and the blood draw; this&#xD;
             interval depends on the type and dosage of HRT. Following confirmation of their&#xD;
             post-menopausal status, they can resume use of HRT during the study without use of a&#xD;
             contraceptive method; Child-bearing potential with negative pregnancy test as&#xD;
             determined by serum human chorionic gonadotropin (hCG) test at screening or urine hCG&#xD;
             prior to dosing AND; Agrees to use one of the contraception methods listed in protocol&#xD;
             for an appropriate period of time (as determined by the product label or investigator)&#xD;
             prior to the start of dosing to sufficiently minimize the risk of pregnancy at that&#xD;
             point. Female subjects must agree to use contraception until follow-up; OR has only&#xD;
             same-sex partners, when this is her preferred and usual lifestyle.&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician, based on a medical&#xD;
             evaluation including medical history, physical examination, laboratory tests and&#xD;
             cardiac monitoring. A subject with a clinical abnormality or laboratory parameter(s)&#xD;
             which is/are not specifically listed in the inclusion or exclusion criteria, outside&#xD;
             the reference range for the population being studied may be included only if the&#xD;
             Investigator agree and document that the finding is unlikely to introduce additional&#xD;
             risk factors and will not interfere with the study procedures.&#xD;
&#xD;
          -  Alanine transaminase, alkaline phosphatase and bilirubin &gt;1.5x upper limit of normal&#xD;
             (ULN) (isolated bilirubin &gt;1.5xULN is acceptable if bilirubin is fractionated and&#xD;
             direct bilirubin &lt;35%).&#xD;
&#xD;
          -  Based on single or averaged corrected QT interval (QTc) values of triplicate ECGs&#xD;
             obtained over a brief recording period: QTcF &lt;450 milliseconds.&#xD;
&#xD;
          -  Current non-smokers who have not used any tobacco- containing products within 3 months&#xD;
             of screening and with a total pack year history of &lt;=10 pack years [number of pack&#xD;
             years = (number of cigarettes per day / 20) x number of years smoked].&#xD;
&#xD;
          -  Able to use all medical device products included in the study adequately after&#xD;
             training&#xD;
&#xD;
        Part B&#xD;
&#xD;
          -  Able to tolerate the charcoal block at screening&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof&#xD;
             (including milk protein allergy) or a history of drug or other allergy that, in the&#xD;
             opinion of the investigator or GSK Medical Monitor, contraindicates their&#xD;
             participation.&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result within 3 months of screening&#xD;
&#xD;
          -  A positive pre-study breath carbon monoxide test or urine drug or breath alcohol&#xD;
             screen.&#xD;
&#xD;
          -  A positive test for HIV antibody.&#xD;
&#xD;
          -  Screening PR interval outside the range 120 to 240msec; or an ECG that is not suitable&#xD;
             for QT measurements (eg poorly defined termination of T-wave)&#xD;
&#xD;
          -  Pregnant or lactating females or females actively trying to conceive.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 millilitres within a 56 day period.&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  An unwillingness to abstain from strenuous exercise starting 72 hours prior to each&#xD;
             dosing day&#xD;
&#xD;
          -  An unwillingness to abstain from caffeine- and xantheine- containing products for 24&#xD;
             hours prior to dosing.&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated&#xD;
&#xD;
        Part B&#xD;
&#xD;
          -  Previous participation in Part A of this study (200921)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>November 7, 2013</study_first_submitted>
  <study_first_submitted_qc>November 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2013</study_first_posted>
  <last_update_submitted>June 18, 2018</last_update_submitted>
  <last_update_submitted_qc>June 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Asthma</keyword>
  <keyword>Respiratory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>200921</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>200921</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>200921</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>200921</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>200921</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>200921</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>200921</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

